Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary Shares

Rhea-AI Summary

Gamida Cell Ltd. (Nasdaq: GMDA) announced a public offering of 8,125,000 ordinary shares priced at $8.00 each, raising $65.0 million in gross proceeds. The offering includes an option for underwriters to purchase an additional 1,218,750 shares. Proceeds will fund the commercial launch of omidubicel, continue clinical development of candidates like GDA-201, and expand manufacturing capabilities. The closing is expected on or about December 21, 2020, pending customary conditions.

Positive

• Funding for potential commercial launch of omidubicel will advance the company’s market position.
• Supports ongoing clinical development of GDA-201, potentially enhancing the product pipeline.
• Expansion of commercial manufacturing capabilities could lead to increased production capacity.

Negative

• Dilution risk for existing shareholders due to the issuance of new shares.
• Market reaction uncertainty as the offering might affect stock price.

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of a follow-on public offering of 8,125,000 ordinary shares at a public offering price of $8.00 per share for aggregate gross proceeds of $65.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Gamida Cell has granted the underwriters a 30-day option to purchase up to an additional 1,218,750 ordinary shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about December 21, 2020, subject to satisfaction of customary closing conditions.

Gamida Cell intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, available for sale and short-term deposits: to fund (i) the preparation of a potential commercial launch of omidubicel; (ii) the continued clinical development of its product candidates, including GDA-201; (iii) the expansion of its commercial manufacturing capabilities; and (iv) general corporate purposes, including general and administrative expenses and working capital.

Piper Sandler & Co., Evercore Group L.L.C. and JMP Securities LLC are acting as joint book-running managers for this offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission on Form F-3 (File No. 333-234701) and declared effective on November 27, 2019. This offering will be made only by means of a prospectus supplement. Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained, when available, from: Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at prospectus@psc.com; Evercore Group L.L.C., 55 East 52nd Street, New York, New York 10055, Attention: Equity Capital Markets, by telephone: (888) 474-0200, or by email: ecm.prospectus@evercore.com; or JMP Securities LLC, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111, Attention: Prospectus Department, by calling (415) 835-8985 or by email at syndicate@jmpsecurities.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Gamida Cell

Gamida Cell is an advanced cell therapy company committed to cures for blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need.

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the use of proceeds and timing of the closing of the public offering. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those that are described in the Risk Factors sections of the preliminary prospectus supplement for such offering filed with the SEC on December 17, 2020, and the documents incorporated by reference therein, including without limitation the Company’s Annual Report on Form 20-F filed with the SEC on February 26, 2020, the accompanying prospectus and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), which could cause the events and circumstances discussed in such forward-looking statements not occur on the terms described or at all. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Gamida Cell undertakes no obligation to update any such forward-looking statements after the date hereof, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005698/en/

FAQ

What is the purpose of Gamida Cell's follow-on public offering announced in December 2020?

The follow-on public offering aims to raise funds for the commercial launch of omidubicel, continue clinical development of GDA-201, and expand manufacturing capabilities.

How many shares is Gamida Cell offering in their December 2020 public offering?

Gamida Cell is offering 8,125,000 ordinary shares in the public offering.

What is the expected closing date for Gamida Cell's public offering?

The offering is expected to close on or about December 21, 2020, subject to customary closing conditions.

What are the gross proceeds from Gamida Cell's public offering?

The public offering is expected to raise aggregate gross proceeds of $65.0 million.

Who are the underwriters for Gamida Cell's public offering?

Piper Sandler & Co., Evercore Group L.L.C., and JMP Securities LLC are acting as joint book-running managers for the offering.